Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Clinical trials sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., explained in plain language.
A pharmaceutical R&D subsidiary of Sino Biopharmaceutical, focusing on drug development.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot could tame seasonal sniffles for good? Results expected Nov 2026 (estimated)
- New antibody injection aims to tame COPD Flare-Ups Results expected Dec 2026 (estimated)
- New antibody injection could shrink nasal polyps and ease breathing Results expected Mar 2027 (estimated)
- Can a smart drug deliver a toxic payload directly to cancer cells? Results expected Aug 2027 (estimated)
-
New shot could bring major relief for severe eczema sufferers
Disease control OngoingThis study tests an experimental injection called TQH2722 in 500 adults with moderate to severe eczema (atopic dermatitis). The goal is to see if it can significantly reduce skin redness, itching, and rash compared to a placebo. Participants receive either the drug or a dummy sho…
Phase 3 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New antibody injection aims to tame COPD Flare-Ups
Disease control OngoingThis Phase 2 trial tests an injection called TQC2731 in 258 adults with moderate-to-severe COPD. The drug blocks a protein linked to airway inflammation. Researchers will measure how well it reduces the number of moderate or severe flare-ups over 24 weeks compared to a placebo.
Phase 2 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC